Gene Symbol | RBM45 |
---|---|
Entrez Gene | 129831 |
Alt Symbol | DRB1, RB-1 |
Species | Human |
Gene Type | protein-coding |
Description | RNA binding motif protein 45 |
Other Description | RNA-binding motif protein 45|RNA-binding protein 45|developmentally regulated RNA-binding protein 1|developmentally-regulated RNA-binding protein 1|putative RNA binding protein RB-1 |
Swissprots | Q8IUH3 Q6NYL0 Q8NFC9 |
Accessions | EAX11044 EAX11045 EAX11046 Q8IUH3 AB036991 BAC16207 AF526533 AAM88417 AK126575 BC037837 BC066549 AAH66549 BI763677 HQ447489 ADQ31975 XM_005246287 XP_005246344 XM_006712261 XP_006712324 NM_152945 NP_694453 |
Function | RNA-binding protein with binding specificity for poly(C). May play an important role in neural development. {ECO:0000250|UniProtKB:Q8CFD1, ECO:0000269|PubMed:12220514}. |
Subcellular Location | Cytoplasm {ECO:0000269|PubMed:12220514}. Nucleus {ECO:0000269|PubMed:12220514}. Note=Predominantly cytoplasmic. May shuttle between cytoplasm and nucleus. |
RBM45 / DRB1 Antibody Blocking Peptide - LS-E4067 from LifeSpan Bioscience
|
||||||||||
RB1 / Retinoblastoma / RB Antibody Blocking Peptide - LS-E9650 from LifeSpan Bioscience
|
||||||||||
RBM45 / DRB1 Antibody Blocking Peptide - LS-E15117 from LifeSpan Bioscience
|
||||||||||
RBM45-Antibody-C-term-Blocking-Peptide - BP16299b from Abgent, a WuXi AppTec company
|
||||||||||
DRB1 Blocking Peptide - 33R-5829 from Fitzgerald
|
||||||||||
HLA-DRB1 protein (His tag) - 80R-3718 from Fitzgerald
|
||||||||||
RBM45 Blocking Peptide - 33R-6375 from Fitzgerald
|
||||||||||
Recombinant Human RNA-binding protein 45(RBM45) - CSB-YP814203HU CSB-EP814203HU CSB-BP814203HU CSB-MP814203HU from Cusabio
|
||||||||||
DRB1 Recombinant Protein Antigen - NBP1-87966PEP from Novus Biologicals
|
||||||||||
RBM45 Peptide, Human - M34GP13070H from Creative Peptides
|
||||||||||
HLA-DRB1 - PAT-82584-1 from Nordic BioSite
|
||||||||||
HLA-DRB1 - PAT-82584-2 from Nordic BioSite
|
||||||||||
RNA-binding protein 45 (RBM45), Recombinant Protein - MBS1434133 from MyBioSource
|
||||||||||